GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook
The FDA approved GSK’s Exdensur (depemokimab-ulaa) on Dec. 17 as a twice-yearly add-on treatment for severe eosinophilic asthma in patients 12 and older. Phase III trials showed up to 58% fewer annual asthma exacerbations versus placebo. The FDA declined approval for a second indication, chronic rhinosinusitis with nasal polyps. GSK faces a leadership change Jan. 1, 2026.